Augmentation Options for Inadequate Response to Vortioxetine 20 mg
Based on the most recent high-quality evidence, you should augment vortioxetine with bupropion SR as the first-line strategy, as this combination has demonstrated similar efficacy to other augmentation approaches with a favorable side effect profile, particularly lower discontinuation rates compared to alternatives like buspirone. 1
Evidence-Based Augmentation Strategies
The 2023 American College of Physicians systematic review and network meta-analysis provides the strongest guidance for managing inadequate antidepressant response 1. This guideline specifically addresses second-step treatments when initial antidepressant therapy fails to achieve remission.
Primary Augmentation Options
Bupropion SR augmentation is supported by the STAR*D trial data showing:
- Similar efficacy to buspirone augmentation for response and remission rates
- Significantly lower discontinuation due to adverse events (12.5% vs. 20.6%; P < 0.001) compared to buspirone 1
- This makes bupropion the preferred augmentation agent from a tolerability standpoint
Alternative augmentation strategies with evidence include:
- Aripiprazole: One trial showed higher remission rates (55.4% vs. 34.0% compared to bupropion; P = 0.031), though this was a higher risk-of-bias study 1
- Cognitive therapy: STAR*D found similar efficacy to medication augmentation, with numerically lower discontinuation rates (9.2% vs. 18.8%; P = 0.086) 1
Historical Context: Lithium Augmentation
While older literature supports lithium augmentation as having "the best evidence" for tricyclic antidepressants 2, the most recent 2023 guideline does not emphasize this strategy for modern SSRIs/SNRIs like vortioxetine. Given the priority to use the most recent high-quality evidence, lithium is not the first-line recommendation here.
Alternative Strategy: Switching vs. Augmentation
The 2023 guideline found no significant difference between switching antidepressants versus augmentation strategies 1. Specifically:
- Switching from one SSRI/SNRI to another (including vortioxetine to desvenlafaxine) showed no superiority
- The 2024 update confirmed these findings 3
However, since you're already on the maximum dose of vortioxetine (20 mg), augmentation is more practical than switching.
Practical Implementation
Step 1: Add bupropion SR
- Start with standard dosing (typically 150 mg daily, can increase to 300-400 mg/day as tolerated)
- Monitor for 4-8 weeks for response
- Watch for activation, insomnia, or increased anxiety
Step 2: If bupropion fails or is not tolerated
- Consider aripiprazole (2-10 mg/day) - particularly if you have residual anhedonia or lack of motivation
- Alternative: Add cognitive behavioral therapy alongside medication
Step 3: If augmentation strategies fail
- Consider switching to a different antidepressant class entirely
- The guideline shows no clear superiority among switch options (duloxetine, escitalopram, sertraline, venlafaxine) 1
Important Caveats
Drug Interactions
The FDA label for vortioxetine notes that if you're taking strong CYP2D6 inhibitors, your vortioxetine dose should be reduced by half 4. Bupropion is a moderate CYP2D6 inhibitor, so theoretically this could increase vortioxetine levels, though this is not typically clinically significant at standard doses.
Discontinuation Considerations
If you eventually need to stop vortioxetine, the FDA recommends tapering from 20 mg to 10 mg for one week before full discontinuation 4.
Sexual Dysfunction
Vortioxetine can cause sexual dysfunction 4. Bupropion augmentation may actually help mitigate this side effect, as bupropion is often used to counteract SSRI-induced sexual dysfunction.
What NOT to Do
- Avoid MAOIs: Absolute contraindication with vortioxetine - must wait 21 days after stopping vortioxetine before starting an MAOI 4
- Celecoxib augmentation: Despite theoretical anti-inflammatory benefits, a 2024 RCT showed no benefit of celecoxib augmentation in treatment-resistant depression 5
Bottom Line Algorithm
- First choice: Add bupropion SR (best tolerability profile)
- Second choice: Add aripiprazole (if anhedonia prominent) or cognitive therapy
- Third choice: Switch to different antidepressant class
- Reassess every 4-8 weeks for adequate trial duration